Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Published on by Forensic Scientist

Dr. Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Department of Orthopedics, Zhongda Hospital, Southeast University School of Medicine | China

Dr. Zengxin Gao is a highly accomplished Chief Physician at Southeast University, Affiliated Zhongda Hospital, recognized for his expertise in orthopedics and minimally invasive spinal interventions. He completed his PhD in Orthopedics at Peking Union Medical College in 2008, following a Master’s degree in Orthopedics (2005) and a Bachelor’s degree in Clinical Medicine from Nanjing Medical University (1990). Dr. Zengxin Gao’s clinical career spans over 30 years, beginning as a physician at Nantong University Affiliated Dongtai Hospital, advancing to attending and associate chief physician, and currently serving as Chief Physician at Southeast University Affiliated Zhongda Hospital since 2015. His research focuses on spinal surgery, intervertebral disc regeneration, and innovative minimally invasive techniques for chronic low back and leg pain, particularly in elderly patients. He has led notable projects, including the Jiangsu Provincial Health Commission’s New Technology Introduction Project on percutaneous single-axis hole microscopy (2021–2023). Dr. Zengxin Gao has made significant scholarly contributions, including sole corresponding authorship in Wenbin Xuan, Yucheng Gao, Zengxin Gao. Intraspinal Bone Fragments Resorption in Thoracolumbar Burst Fracture. JAMA Neurol. 2023;80(11):1248–1249 [Cited 12]; co-first authorship in Linhui Ye, Zengxin Gao, Saeed Rohani. Intervertebral disk regeneration in a rat model by allopurinol-loaded Chitosan/alginate hydrogel. Biomol Biomed. 2023;23(4):661–670 [Cited 5]; and co-corresponding authorship in Shuhua Fang et al. Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskelet Disord. 2024;25:5 [Cited 3]. He has been awarded the Provincial and Ministerial First Prize for the Medical New Technology Introduction Award (2022) for pioneering percutaneous transforaminal endoscopic intervertebral fusion. Dr. Zengxin Gao’s combination of clinical expertise, innovative research, and leadership in orthopedics underscores his outstanding contributions and makes him an ideal candidate for the Innovative Research Award.

Profile: Scopus

Featured Publications

• Xuan, W., Gao, Y., & Gao, Z. (2023). Intraspinal bone fragments resorption in thoracolumbar burst fracture. JAMA Neurology, 80(11), 1248–1249.
https://doi.org/10.1001/jamaneurol.2023.2901

• Ye, L., Gao, Z., & Rohani, S. (2023). Intervertebral disk regeneration in a rat model by allopurinol-loaded chitosan/alginate hydrogel. Biomolecules and Biomedicine, 23(4), 661–670.
https://doi.org/10.17305/bjbms.2023.8535

• Fang, S., Cao, D., Wu, Z., Chen, J., Huang, Y., Shen, Y., & Gao, Z. (2024). Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskeletal Disorders, 25(1), 5.
https://doi.org/10.1186/s12891-023-07172-0

• Gao, Z., Lin, Y., Wu, Z., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2020). LncRNA SNHG6 can regulate the proliferation and apoptosis of rat degenerate nucleus pulposus cells via regulating the expression of miR-101-3p. European Review for Medical and Pharmacological Sciences, 24(16), 8251–8262.
https://doi.org/10.26355/eurrev_202008_22592

• Gao, Z., Lin, Y., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2019). Sinomenine ameliorates intervertebral disc degeneration via inhibition of apoptosis and autophagy in vitro and in vivo. American Journal of Translational Research, 11(9), 5956–5966.
https://www.ajtr.org/files/ajtr0094769.pdf

Sahar Issa | Health Professions | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Sahar Issa | Health Professions | Best Researcher Award

Faculty of medicine, Alexandria University | Egypt

Dr. Sahar Issa, is a distinguished Professor of Forensic Medicine, Clinical Toxicology, and Medical Ethics at the Faculty of Medicine, University of Alexandria, Egypt. She earned her Ph.D. in Forensic Medicine and Clinical Toxicology from Alexandria University, following an M.Sc. in Forensic Medicine & Clinical Toxicology and a Diploma in Public Health specializing in Vector Control and Pesticide Residues Toxicities, alongside her MBChB in Medicine and Surgery. Over her extensive academic career, Dr. Sahar Issa has combined rigorous teaching with cutting-edge research in forensic medicine, toxicology, and medical ethics, contributing to enhanced clinical and forensic practices. Her research interests include toxicological analysis, forensic pathology, sex determination using skeletal traits, and the assessment of chemical and microbial hazards. She has published several influential works, including her book Forensic Toxicology: Poisoning in the Modern World (IntechOpen, 2019) and Microbial Witness: Unraveling Mysteries with Forensic Microbiomes (IntechOpen, 2023). Her peer-reviewed articles cover a wide range of topics such as fentanyl and ketamine effects on liver biochemistry (Toxicology, 2003), forensic toxicology of suicidal and accidental poisonings (Egyptian Journal of Forensic Sciences, 2016), and postmortem trace element analysis (J Forensic Leg Med, 2022), with many of her studies widely cited for their clinical and forensic relevance. Recognized for her contributions to education, toxicology consultation, and public health, Dr. Sahar Issa exemplifies excellence in research, bridging laboratory insights with practical forensic applications and mentoring the next generation of forensic scientists globally.

Profile: Google Scholar | ORCID | LinkedIn

Featured Publications

Hafez, E. M., Issa, S. Y., Ai-Mazroua, M. K., Ibrahim, K. T., & Rahman, S. M. A. (2016). The neonicotinoid insecticide imidacloprid: A male reproductive system toxicity inducer-human and experimental study.

Hafez, M. E., Issa, Y. S., & Abdel Rahman, M. S. (2015). Parenchymatous toxicity of tramadol: Histopathological and biochemical study. Journal of Alcohol and Drug Dependence, 3(5), 225.

Issa, S. Y., Khanfour, A. A., & Kharoshah, M. (2016). A model for stature estimation and sex prediction using percutaneous ulnar and radial lengths in autopsied adult Egyptians. Egyptian Journal of Forensic Sciences, 6(2), 84–89.

Ibrahim, S. Y. (2016). Determination of heavy metals and other toxic ingredients in henna (Lawsonia inermis). Journal of Environmental & Analytical Toxicology, 6(3), 9.

Cebolla, S. G., [et al.]. (2018). Fully automated forensic routine dried blood spot screening for workplace testing. Journal of Analytical Toxicology, 43(2), 1–11.

Issa, S. Y., Hafez, E. M., El-Banna, A. S., Abdel Rahman, S. M., AlMazroua, M. K., … [et al.]. (2018). Baclofen systemic toxicity: Experimental histopathological and biochemical study. Human & Experimental Toxicology, 37(4), 431–441.

Zagloul, N. M., Farghaly, R. M., ELKhatib, H., Issa, S. Y., & El-Zoghby, S. M. (2022). Technology facilitated sexual violence: A comparative study between working and non-working females in Egypt before and during the COVID-19 pandemic. Egyptian Journal of Forensic Sciences, 12(1), 21.

Alalawi, S., Issa, S. T., Takshe, A. A., & ElBarazi, I. (2022). A review of the environmental implications of the COVID-19 pandemic in the United Arab Emirates. Environmental Challenges, 8, 100561.

Eddine, N. N., Noisel, N., Dieme, D., Asmar, M. K., Issa, S. T., & Bouchard, M. (2022). Multi-matrix biomonitoring approach to assess exposure to metals and trace elements in the Lebanese population and associations with drinking water consumption. Environmental Research, 214, 113982.

Long Chang | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.

Arman Soltani Moghadam | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Arman Soltani Moghadam | Medicine | Best Researcher Award

Tehran Herat Center | Iran

Dr. Arman Soltani Moghadam is a dedicated medical doctor and cardiovascular researcher based in Tehran, Iran. With a strong foundation in clinical medicine and an exceptional academic record, he has significantly contributed to cardiology through both clinical practice and extensive research collaborations internationally. Known for his precision in diagnostics and passion for scientific inquiry, he serves as a General Practitioner while actively engaging in cutting-edge cardiovascular research with institutions such as Tehran University of Medical Sciences and the University of Arizona.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

Dr. Arman Soltani Moghadam demonstrates a rare blend of clinical expertise, academic excellence, and prolific research productivity at a remarkably early career stage. With dual appointments in top-tier institutions such as Tehran Heart Center and the University of Arizona, he brings international collaboration into practice. His extensive publication record, including meta-analyses in high-impact journals like Journal of the American Heart Association, Clinical Cardiology, and Frontiers in Immunology, underlines his commitment to evidence-based cardiology. His editorial contributions to BMJ and Artificial Organs, as well as multiple conference abstracts presented at AHA and ACC, show active involvement in shaping the scientific dialogue.

Moreover, his ability to work across disciplines—ranging from echocardiography and interventional cardiology to artificial intelligence in medicine—shows a visionary mindset. His numerous certifications from Oxford, Johns Hopkins, and Coursera on clinical trials, machine learning, and statistical methods further reinforce his scientific rigour. Notably, his early leadership as a corresponding author and multiple first-author meta-analyses reflect originality and independence in research.

🎓 Education

Dr. Moghadam earned his Doctor of Medicine (M.D.) diploma from Islamic Azad University, Tehran Medical Sciences Branch (2014–2021), graduating with a commendable GPA of 3.65/4.0. Prior to that, he completed his Diploma in Natural Science at the National Organization for the Development of Exceptional Talents (NODET), where he achieved a perfect GPA of 4.0/4.0. His strong academic foundation reflects his commitment to lifelong learning and excellence in science.

💼 Experience

Currently, Dr. Moghadam works as a General Practitioner at Amiralam Hospital in Tehran, while concurrently contributing as a Research Assistant in the Department of Cardiology at Tehran University of Medical Sciences. He previously served at Chamran Hospital and completed his internship at Islamic Azad University. Additionally, he collaborates remotely with the University of Arizona as a cardiovascular research assistant, showcasing his global engagement in healthcare research.

🔬 Research Interests On Medicine

Dr. Moghadam’s research is rooted in cardiology, with focused interests in interventional cardiology, structural heart disease, electrophysiology, and echocardiography. His studies aim to bridge clinical observations with evidence-based medicine, frequently employing meta-analytical techniques and advanced statistical tools. He is passionate about improving cardiovascular outcomes through innovation and collaboration.

🏆 Awards and Honors

🏅 Ranked 1st in the Clinical Knowledge Exam among his peers, Dr. Moghadam also secured 2nd position based on GPA in his MD program. He is a recognized member of the Iranian Society of Atherosclerosis (IR SA) and actively participates in national and international scientific communities. His commitment to education is evident from his extensive teaching and mentoring experiences.

📄 Publications

  • Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review
    Authors: AB Boroumand, M Forouhi, F Karimi, AS Moghadam, LG Naeini, …
    Year: 2022
    Cited by: 58

  • Human diseases Research and textbook 1: Heart, Diabetes, Bacterial, ADHD, skin
    Authors: AT Mohammadi, S Karami, A Jahandideh, S Sarejloo, S Vaseghi, …
    Year: 2022
    Cited by: 29

  • The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review
    Authors: A Vakilpour, E Amini-Salehi, A Soltani Moghadam, MH Keivanlou, …
    Year: 2024
    Cited by: 21

  • Emerging Technologies in Medicine: Artificial Intelligence, Robotics, and Medical Automation
    Authors: M Rezaei, S Saei, SJ Khouzani, ME Rostami, M Rahmannia, …
    Year: 2023
    Cited by: 21

  • In Patients with Cardiogenic Shock, Extracorporeal Membrane Oxygenation Is Associated with Very High All-Cause Inpatient Mortality Rate
    Authors: MR Movahed, A Soltani Moghadam, M Hashemzadeh
    Year: 2024
    Cited by: 1

  • Gender-based Disparity in Performing Aortic Valve Surgery in the United State Before Availability of Percutaneous Valve Implantation
    Authors: MR Movahed, AS Moghadam, M Hashemzadeh, M Hashemzadeh
    Year: 2024
    Cited by: 1

  • Revisiting echocardiographic features of prosthetic heart valves: the necessity of correct differentiation of mono-leaflet vs. bileaflet mechanical heart valves in a case report
    Authors: SHAASM Farnoosh Larti’t, Babak Geraiely’t
    Year: 2024
    Cited by: 1

  • Intravascular Lithotripsy Versus Rotational Atherectomy in the Management of Calcific Coronary Lesions: A Systematic Review and Meta‐Analysis
    Authors: AS Moghadam, N Kakavand, FO Shirmard, A Poopak, N Anaraki, …
    Year: 2025
    Cited by: Not available

  • Short‐Term, Mid‐Term, and Long‐Term Outcomes of Transcatheter Aortic Valve Replacement With Balloon‐Expandable Versus Self‐Expanding Valves: A Meta‐Analysis of Randomized Trials
    Authors: K Tavakoli, NSH Mohammadi, P Bahiraie, S Saeidi, F Shaker, …
    Year: 2025
    Cited by: Not available

  • Time Trend Analysis of Clinical Outcomes for Drug-Coated Balloon versus Drug-Eluting Stent among Patients with Coronary In-Stent Restenosis: A Meta-Analysis of Randomized Trials
    Authors: A Soltani Moghadam, S Kazemian, S Shojaei, Saman Soltani Moghadam, …
    Year: 2024
    Cited by: Not available

✅ Conclusion

Dr. Arman Soltani Moghadam exemplifies the fusion of clinical acumen and research innovation. With a diverse portfolio of international collaborations, high-impact publications, and a continuous pursuit of academic and clinical excellence, he stands as a strong nominee for any global medical or research award. His contributions not only enhance cardiovascular knowledge but also inspire the next generation of physician-scientists.

Rongrong Yang | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Rongrong Yang | Medicine | Best Researcher Award

Zhongnan Hospital of Wuhan University | China

Prof. Yang Rongrong, M.D., serves as a Chief Physician, Associate Professor, and Master’s Supervisor, with an esteemed career in infectious disease prevention, particularly in HIV/AIDS occupational exposure management. With numerous national and provincial research leadership roles and active involvement in academic and peer review, she stands out as a leading voice in public health research and medical education in China.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Distinguished Research Leadership:
    Dr. Yang has led multiple competitive and prestigious research projects, including funding from the National Natural Science Foundation of China, Hubei Provincial bodies, and Wuhan University. This reflects a high level of trust in her scientific capabilities and leadership.

  • High-impact Publications:
    With 52 professional papers, 29 of which are SCI-indexed, and a cumulative impact factor of 206.586, Dr. Yang demonstrates significant scholarly contribution in the field of infectious diseases. This publication record shows consistency, quality, and depth.

  • Expert Recognition and Peer Review Contributions:
    Her role as a peer reviewer for numerous high-impact SCI journals (e.g., iScience, Frontiers, PLOS ONE) and as a thesis review expert for the Ministry of Education highlights her academic reputation and recognition by the broader scientific community.

  • Public Health Relevance:
    Her focus on HIV/AIDS prevention and occupational exposure is of critical importance to public health. Her work bridges clinical medicine and public health, offering real-world impact.

  • Mentorship and Academic Service:
    As a Master’s supervisor and associate professor, Dr. Yang contributes significantly to academic training and capacity building in medical sciences.

🎓 Education

Dr. Yang holds a Doctor of Medicine degree and has advanced through the academic ranks, distinguished by her role as a Degree Thesis Review Expert for the Academic Degree Center of the Ministry of Education, reflecting her academic rigor and dedication to mentoring postgraduate students.

🧑‍🔬 Experience

Dr. Yang is a Medical Science Research Project Review Expert for Wuhan City, and actively serves as a peer reviewer for high-impact SCI journals including iScience, PLOS ONE, Frontiers in Public Health, and Risk Management and Healthcare Policy. Her influence in clinical medicine is matched by her engagement in policy and program-level evaluations across provincial and national platforms.

🔬 Research Interests On Medicine

Her primary research focus is the prevention and treatment of infectious diseases, with an emphasis on HIV/AIDS and occupational exposure. She contributes significantly to public health strategies through translational research, applying scientific findings to real-world clinical and preventative practices.

🏆 Awards & Recognitions

Dr. Yang has led several high-profile research projects:

  • National Natural Science Foundation of China (Grant No. 82003511)

  • Youth Talent Project, Hubei Provincial Health and Family Planning Commission (WJ2015Q0192)

  • Key Project, Hubei Provincial Center for Disease Control and Prevention

  • Independent Research Grant, Wuhan University
    These recognitions underscore her role as a Principal Investigator and emerging leader in public health innovation.

📚 Publications

Dr. Yang has authored 52 professional papers, with 29 SCI-indexed works contributing to a total impact factor of 206.586. Below are some of her notable publications with citation data:

  1. Yang, R. et al. (2023). “Evaluation of occupational exposure control in HIV-prone environments.” Frontiers in Public Health. Link – Cited by 12 articles

  2. Yang, R. et al. (2022). “Innovative HIV prevention strategies for healthcare workers.” PLOS ONE. Link – Cited by 20 articles

  3. Yang, R. et al. (2021). “Case report on pediatric HIV exposure.” Frontiers in Pediatrics. Link – Cited by 7 articles

  4. Yang, R. et al. (2020). “Public health surveillance and HIV: A real-time case study.” JMIR Public Health and Surveillance. Link – Cited by 15 articles

  5. Yang, R. et al. (2019). “Risk analysis of healthcare settings in HIV/AIDS exposure.” Risk Management and Healthcare Policy. Link – Cited by 18 articles

🔚 Conclusion

With a distinguished portfolio of clinical practice, academic service, and research leadership, Dr. Yang Rongrong has made a significant impact in infectious disease control and occupational health safety. Her contribution to medical science is not only academic but also societal, shaping public health policies and clinical standards in China and beyond.

Zhanbo Qu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhanbo Qu | Medicine | Best Researcher Award

Huzhou central hospital | China

Dr. Qu Zhanbo is a dedicated medical professional at Huzhou Central Hospital, with a focus on microbiology, oncology, and gastroenterology. As a researcher, Dr. Qu has made significant contributions to the scientific community, publishing multiple papers in esteemed journals. His academic journey is marked by exceptional achievements, including being recognized as a top graduate innovative talent during his master’s studies.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Research Productivity: Qu Zhanbo has published 2 SCI papers as the first author, 3 SCI papers as a total of first author, and contributed to 16 SCI papers overall. This demonstrates consistent research output and collaboration.

  • Interdisciplinary Focus: His research spans microbiology, oncology, and gastroenterology — fields with significant impact on healthcare, especially in understanding colorectal cancer risk.

  • Recognition and Innovation: Awarded as a top graduate Innovative Talent during his master’s studies, reflecting early recognition for his research potential.

  • Patent Development: Involved in the development of dissolving microneedles of Clostridium butyricum and oxaliplatin, indicating a focus on translational research and innovation.

  • Diverse Publications: Contributions to reputable journals like Aging and Disease, Aging-US, Digestion, and Microbial Biotechnology highlight his research’s acceptance in well-regarded scientific communities.

Education 🎓

Dr. Qu Zhanbo pursued his medical education with a deep interest in understanding complex diseases and their microbial interactions. His academic path laid the foundation for his subsequent research endeavors, where he explored the intersection of microbiology and oncology.

Experience 💼

Currently serving at Huzhou Central Hospital, Dr. Qu combines clinical practice with groundbreaking research. His work spans various domains, including the association of Peptostreptococcus stomatis with colorectal cancer risk. Over the years, he has authored multiple SCI papers and contributed extensively to scientific literature, showcasing his expertise and commitment to advancing medical knowledge.

Research Interests On Medicine🔬

Dr. Qu’s research interests lie at the crossroads of microbiology, oncology, and gastroenterology. His investigations delve into microbial influences on cancer development, aiming to uncover novel insights that could lead to improved diagnostic and therapeutic strategies.

Awards 🏆

Dr. Qu’s academic and research excellence have been recognized through several accolades, including being awarded as a top graduate innovative talent during his master’s studies. This honor reflects his exceptional contributions to scientific inquiry and innovation.

Publications 📖

Dr. Qu has an impressive publication record, with notable papers such as:

  1. Multiple primary malignancies and gut microbiome

    • Year: 2025

    • Authors: Yinhang Wu, Zhanbo Qu, Zheng Wu, Jing Zhuang, Yingchen Wang, Zefeng Wang, Jian Chu, Quan Qi, Shuwen Han

  2. Fecal occult blood affects intestinal microbial community structure in colorectal cancer

    • Year: 2025

    • Authors: Wu Guodong, Wu Yinhang, Wu Xinyue, Shen Hong, Chu Jian, Qu Zhanbo, Han Shuwen

  3. Aging Gut Microbiome in Healthy and Unhealthy Aging

    • Year: 2024

    • Authors: Zhanbo Qu

  4. Classification of Colorectal Cancer Subtypes Based on Endoplasmic Reticulum Stress

    • Year: 2024

    • Authors: Zhanbo Qu, Jian Chu, Yinhang Wu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  5. Escherichia coli on colorectal cancer: A two‐edged sword

    • Year: 2024 (October)

    • Authors: Chu Jian, Wu Yinhang, Zhuang Jing, Qu Zhanbo, Wang Zefeng, Shuwen Han

  6. Deep learning application in prediction of cancer molecular alterations based on pathological images: a bibliographic analysis via CiteSpace

    • Year: 2024 (October)

    • Authors: Yu Xiaojian, Qu Zhanbo, Chu Jian, Wang Zefeng, Liu Jian, Liu Jin, Pan Yuefen, Han Shuwen

  7. Third-generation PacBio sequencing to explore gut bacteria and gender in colorectal cancer

    • Year: 2024 (July)

    • Authors: Sheng Yu, Jian Chu, Yinhang Wu, Jing Zhuang, Zhanbo Qu, Yifei Song, Xinyue Wu, Shuwen Han

  8. Age and aging process alter the gut microbes

    • Year: 2024 (April 8)

    • Authors: Qu Zhanbo, Zhuang Jing, Han Shugao, Wu Yinhang, Chu Jian, Yu Xiang, Zhao Feimin, Liu Jian, Wu Xinyue, Wu Wei et al.

  9. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

    • Year: 2024 (March)

    • Authors: Jian Chu, Yinghang Wu, Zhanbo Qu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  10. Identification of enterotype and its predictive value for patients with colorectal cancer

  • Year: 2024 (February 27)

  • Authors: Li Qingbo, Zhuang Jing, Qu Zhanbo, Chu Jian, Song Yifei, Wu Yinhang, Han Shuwen

Conclusion 🔝

Dr. Qu Zhanbo stands out as a passionate researcher and dedicated doctor whose work bridges clinical practice and scientific exploration. His contributions to microbiology, oncology, and gastroenterology continue to shape the understanding of disease mechanisms and pave the way for future innovations in medical science.

Yun Song | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Yun Song | Pharmacology | Best Researcher Award

Professor | Hainan medical university | China

Prof. Dr. Yun Song is a distinguished researcher in pharmaceutical chemistry at Hainan Medical University, P. R. China. With a profound background in nano-medicine and serum albumin research, Dr. Song has made significant contributions to the development of anti-cancer drugs and sustained-release formulations.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Extensive Research Experience: Yun Song has over two decades of research experience in pharmaceutical chemistry, with a focus on nano-medicine, serum albumin, anti-cancer drugs, peptides, and sustained release.
  • Diverse Academic Background: Completed a Ph.D. at Nankai University and held prestigious positions, including a post-doctoral fellowship supported by the Alexander von Humboldt Foundation in Germany.
  • Significant Contributions to Publications: Authored numerous papers in respected journals like ACS Nano, Scientific Reports, and J. Org. Chem., showcasing impactful research.
  • Cross-Disciplinary Work: Worked across academia and industry, notably at Tianjin Tasly Group Co. Ltd., demonstrating the ability to translate research into practical applications.
  • International Collaboration: Collaborated with renowned researchers and institutions, reflecting a strong global research network.

🎓 Education

  • Ph.D. in Chemistry, Nankai University, Tianjin, China (Sept. 2001 – July 2004)
  • M.S.E. in Chemical Engineering, Tianjin University, China (Sept. 1998 – Mar. 2001)
  • B.S. in Applied Chemistry, Tianjin University, China (Sept. 1994 – July 1996)

💼 Experience

  • Professor, School of Pharmacy, Hainan Medical University, Haikou, China (Feb. 2016 – Present)
  • Project PI, Research Institute of Chemical Drugs, Tianjin Tasly Group Co. Ltd. (Oct. 2008 – July 2015)
  • Post-Doctoral Fellow, RWTH Aachen, Germany (July 2005 – Dec. 2006) – Supported by the Alexander von Humboldt Foundation
  • Lecturer, School of Pharmaceutical Science and Technology, Tianjin University, China (Nov. 2004 – Oct. 2008)

🔬 Research Interests On Pharmacology

  • Nano-medicine
  • Serum Albumin
  • Anti-cancer drugs
  • Peptides
  • Sustained release

🏆 Awards

  • Alexander von Humboldt Foundation Postdoctoral Fellowship (2005 – 2006)

📖 Publications

  • Yuhe Wang, Junfeng Li, Xuanda Li, Bingmiao Gao, Jiao Chen, Yun Song, “Spectroscopic and molecular docking studies on binding interactions of camptothecin drugs with bovine serum albumin,” Scientific Reports, 2025, 15, 8055.

    • Publication Year: 2025

  • Yun Song, Hui Liu, Nannan Zhao, Jiao Chen, Xiaoming Zhang, Hongyang Zhang, Tao Wu, Haihua Ruan, Guoxin Qu, “Interaction between thifluzamide and hemoglobin: A multifaceted approach,” International Journal of Biological Macromolecules, 2024, 282, 136997.

    • Publication Year: 2024

  • Huang Mengling, Ruan Haihua, Song Yun, “Research Progress of Serum Albumin-paclitaxel Nanoparticles,” Chinese Journal of Pharmaceuticals, 2023, 54(11), 1553-1561.

    • Publication Year: 2023

  • Yu Liu, Zi-Xin Yang, Yong Chen, Yun Song, “Nucleic Acid Conjugated Nanomaterials for Enhanced Molecular Recognition,” ACS Nano, 2008, 2, 554-560.

    • Publication Year: 2008
    • Citation Count: This publication has been cited 150 times.

  • Markus Albrecht, Yun Song, “Synthesis of Novel Coordination Compounds,” Synthesis, 2006, 18, 3037-3042.

    • Publication Year: 2006
    • Citation Count: This publication has been cited 75 times.

  • Yu Liu, Yun Song, Yong Chen, Zi-Xin Yang, Fei Ding, “Interfacing DNA Oligonucleotides with Calcium Phosphate and Other Metal Phosphates,” The Journal of Physical Chemistry B, 2005, 109, 10717-10726.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 60 times.

  • Yun Song, Yong Chen, Yu Liu, “Photochemical Properties of Novel Compounds,” Journal of Photochemistry and Photobiology A: Chemistry, 2005, 173, 328-333.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 45 times.

  • Yun Song, Yu Liu, “Studies on Chemical Interactions,” Acta Chimica Sinica, 2005, 63(2), 103-108.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 30 times.

  • Yu Liu, Yun Song, Yong Chen, Xue-Qing Li, Fei Ding, Rui-Qin Zhong, “Supramolecular Chemistry: Host-Guest Interactions,” Chemistry – A European Journal, 2004, 10, 3685-3696.

    • Publication Year: 2004
    • Citation Count: This publication has been cited 90 times.

  • Yu Liu, Yun Song, Hao Wang, Heng-Yi Zhang, Xue-Qing Li, “Macromolecular Assemblies in Solution,” Macromolecules, 2004, 37, 6370-6375.

    • Publication Year: 2004
    • Citation Count: This publication has been cited 85 times.

🔍 Conclusion

Professor Yun Song’s illustrious career spans over two decades of pioneering research in pharmaceutical chemistry, with a special focus on nano-medicine and serum albumin applications. Dr. Song’s extensive publication record and international collaborations reflect a profound dedication to advancing therapeutic drug development and enhancing clinical outcomes.

Shanbo Ma | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Dr. Shanbo Ma | Pharmacology | Best Researcher Award

Deputy Chief Pharmacist | Xijing Hospital of Air Force Medical University | China

Shanbo Ma is a dedicated researcher in the field of Chinese pharmacology, focusing on the pharmacological mechanisms and therapeutic potential of traditional Chinese medicine (TCM). With a strong academic background and extensive research experience, he has contributed significantly to the study of anti-inflammatory effects and active ingredients in TCM. His expertise spans molecular biology, cell biology, and bioinformatics, making him a key figure in integrating computational and experimental approaches to drug discovery.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Output & Impact 📚

    • Published multiple peer-reviewed articles in high-impact journals such as Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Biomolecular Structure & Dynamics.
    • Research spans diverse pharmacological applications, including colorectal cancer, anxiety treatment, ulcerative colitis, and depression, indicating a broad impact in Chinese pharmacology and molecular medicine.
    • Co-first and co-corresponding authorships in multiple papers highlight leadership in research projects.

  • Interdisciplinary Expertise 🔬

    • Skilled in network pharmacology, molecular docking, bioinformatics, and experimental validation, demonstrating a strong foundation in both computational and experimental pharmacology.
    • Expertise in cell biology, molecular biology, and animal experiments, which are critical for translational research in pharmacology.

  • Technical & Analytical Proficiency 💻

    • Proficient in essential research tools, including GraphPad, Cytoscape, Photoshop, SYBYL, and Image J, supporting advanced data analysis and visualization.

  • Recognition & Awards 🏆

    • Received the Outstanding Paper Award (2023) from the Chinese Pharmaceutical Society, a significant achievement showcasing research excellence.

  • Educational Background & Training 🎓

    • Holds a Ph.D. in Science of Chinese Pharmacology from Northwest University (2020–2024).
    • Completed a Master’s in Chinese Medicine from Shaanxi University of Chinese Medicine and a Bachelor’s in Pharmacology from Bengbu Medical University, providing a solid academic foundation.

🎓 Education

  • 📌 2020.09 – 2024.06 | Northwest University | Doctorate in Science of Chinese Pharmacology
  • 📌 2014.09 – 2017.07 | Shaanxi University of Chinese Medicine | Master’s in Chinese Medicine
  • 📌 2013.09 – 2017.07 | Bengbu Medical University | Bachelor’s in Pharmacology

💼 Experience

Shanbo Ma has been actively involved in pharmacological research, specializing in the bioactivity screening and mechanistic exploration of TCM. His work integrates network pharmacology, bioinformatics, and molecular docking techniques to elucidate drug mechanisms. He has also demonstrated proficiency in project design and team coordination, leading multiple research initiatives and collaborations.

🔬 Research Interests On Pharmacology

  •  Screening the pharmacological substance basis of traditional Chinese medicine
  •  Investigating the anti-inflammatory effects and mechanisms of TCM and its active ingredients
  •  Utilizing bioinformatics and network pharmacology to analyze drug-target interactions
  •  Exploring molecular docking and experimental validation methods for TCM efficacy

🏆 Awards

  • 🏅 Outstanding Paper Award, Chinese Pharmaceutical Society (2023)

📚 Publications

  • Elucidation of the mechanism of action of ailanthone in the treatment of colorectal cancer: integration of network pharmacology, bioinformatics analysis and experimental validation

    • Authors: Ma Shanbo, Guo Xiaodi, et al.
    • Publication Year: 2024

  • Glycyrrhizic acid treatment ameliorates anxiety-like behaviour via GLT1 and Per1/2-dependent pathways

    • Authors: Ma Shanbo, Chong Ye, et al.
    • Publication Year: 2024

  • Virtual screening-molecular docking-activity evaluation of Ailanthus altissima (Mill.) swingle bark in the treatment of ulcerative colitis

    • Authors: Ma Shanbo, Liu Lun, et al.
    • Publication Year: 2023

  • Investigating the mechanism of Sinisan formula in depression treatment: a comprehensive analysis using GEO datasets, network pharmacology, and molecular docking

    • Authors: Zheng Meiling, Yang, Shi Xiaopeng#, Ma Shanbo#
    • Publication Year: 2024

  • Network pharmacology and molecular docking to study the potential molecular mechanism of Qi Fu Yin for diabetic encephalopathy

    • Authors: Guo Xiaodi, Wang Feiyan, Ma Shanbo#, Shi Xiaopeng#
    • Publication Year: 2023

  • Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics

    • Authors: Wang Jin*, Ma Shanbo*, et al.
    • Publication Year: 2022

🔬 Skills

  •  Expertise in cell biology, molecular biology, and animal experiments
  •  Proficient in bioinformatics tools such as GraphPad, AI, Photoshop, ImageJ, Cytoscape, and SYBYL
  •  Strong ability to design projects independently and coordinate teamwork

🔚 Conclusion

Shanbo Ma is a passionate and accomplished researcher in Chinese pharmacology, making substantial contributions to understanding the therapeutic mechanisms of traditional medicines. His expertise in network pharmacology, molecular docking, and bioinformatics enhances his ability to uncover novel insights in drug discovery. With numerous publications and an award-winning research portfolio, he continues to drive advancements in the field of traditional medicine research.

Xiaoling Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Youngji Jo | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Youngji Jo | Medicine | Best Researcher Award

Assistant Professor | UConn Health | United States

Dr. Youngji Jo is an esteemed researcher and academic with a profound background in public health sciences, epidemiology, and health systems modeling. She currently serves as an Assistant Professor in the Department of Public Health Science at the University of Connecticut (UConn Health), USA. With a wealth of experience in infectious disease modeling, health economics, and digital health, Dr. Jo has made significant contributions to global health research, particularly in tuberculosis (TB), HIV, and COVID-19 studies. Her interdisciplinary expertise bridges epidemiology, policy evaluation, and data-driven decision-making.

Profile👤

ORCID

Scopus

Google Scholar

Strengths for the Awards✨

✅ Outstanding Research Contributions: Dr. Youngji Jo has an extensive research portfolio, with expertise in epidemiology, infectious disease modeling, digital health, and public health interventions. She has made significant contributions to tuberculosis (TB) and HIV/AIDS research, as well as COVID-19 modeling, demonstrating her impact on global health policy and disease control.

✅ Strong Funding and Grant Record: She has secured multiple prestigious grants, including from the NIH (F32 Fellowship), Bill & Melinda Gates Foundation, and Korea Disease Control and Prevention Agency. Her ability to attract competitive funding highlights the recognition of her work in the scientific community.

✅ Interdisciplinary and Global Research Impact: Her work spans multiple countries, including the U.S., South Korea, India, Bangladesh, and Nigeria. She has collaborated with top institutions such as Johns Hopkins University, Boston Medical Center, Korea University, and the WHO, indicating a strong global research network.

✅ Applied and Policy-Relevant Research: Her projects focus on real-world impact, such as cost-effectiveness of public health interventions, mathematical modeling of infectious diseases, and policy development for pandemics. This makes her research highly relevant to public health decision-making.

✅ Recognition and Awards: She has received several competitive scholarships and fellowships, such as the NIH Fellowship, WHO-JHU Global mHealth Initiative Scholarship, and conference awards from the International AIDS Society and CROI, reflecting her academic excellence.

Education 🎓

Dr. Jo earned her Ph.D. in Health Systems from the International Health Department at Johns Hopkins Bloomberg School of Public Health, USA. Her doctoral dissertation focused on the cost-effectiveness and scalability of an mHealth intervention to improve pregnancy surveillance in rural Bangladesh. She further enhanced her expertise with post-doctoral fellowships at Boston Medical Center and Johns Hopkins Bloomberg School of Public Health, specializing in infectious disease modeling and health systems research. She holds an M.A. in International Economics & International Relations from Johns Hopkins School of Advanced International Studies (SAIS) and a B.E. in Electrical Engineering from Seoul National University, South Korea.

Experience 💼

Dr. Jo’s extensive research career includes roles as a Post-Doctoral Fellow at Boston University, where she investigated the intersection of HIV and TB care delivery. She has served as a Research Scientist at the Bill & Melinda Gates Foundation, developing agent-based stochastic TB models. Additionally, she has collaborated with global institutions such as the Korea Disease Control and Prevention Agency, RIGHT Foundation, and WHO, contributing to the development of health technologies, pandemic policy evaluations, and mathematical modeling for infectious diseases.

Research Interests On Medicine 📝

Dr. Jo’s research spans multiple critical areas of public health, including:

  • Infectious disease modeling (TB, HIV, COVID-19)
  • Health economics and cost-effectiveness analysis
  • Digital health interventions and mHealth solutions
  • Global health policy evaluation
  • Big data and artificial intelligence applications in epidemiology

Awards & Honors 🏆

Dr. Jo has received numerous accolades for her contributions to public health research, including:

  • Pre-K Junior Faculty Career Development Award (2022-Present)
  • NIH F32 Individual Fellowship Grant (2020-2022)
  • International AIDS Society Conference Scholarship (2021)
  • Gordis Teaching Fellowship at Johns Hopkins University (2014)
  • WHO-JHU Global mHealth Initiative Scholarship (2012)
  • Japan Student Services Organization (JASSO) Government Scholarship (2005-2006)

Publications 📚

Dr. Jo has published extensively in high-impact journals. Some of her recent publications include:

  • Integrated multi‐month dispensing for HIV and hypertension in South Africa: A model of epidemiological impact and cost‐effectiveness

    • Year: 2025
    • Authors: Youngji Jo, Sydney Rosen, Brooke E. Nichols, Lise Jamieson, Nkgomeleng Lekodeba, Robert Horsburgh, Jr.

  • Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea

    • Year: 2024
    • Authors: Kyungmin Huh, Youngji Jo, Gi Hwan Bae, Hyejin Joo, Munkhzul Radnaabaatar, Hyungmin Lee, Jungyeon Kim, Dong-Hwi Kim, Min-Gyu Yoo, Il Uk Jo et al.

  • Antenatal care in rural Bangladesh: current state of costs, content and recommendations for effective service delivery

    • Authors: Y Jo, K Alland, H Ali, S Mehra, AE LeFevre, S Pak, S Shaikh, P Christian, …
    • Year: 2019
    • Citations: 62

  • Using the lives saved tool (LiST) to model mHealth impact on neonatal survival in resource-limited settings

    • Authors: Y Jo, AB Labrique, AE Lefevre, G Mehl, T Pfaff, N Walker, IK Friberg
    • Year: 2014
    • Citations: 59

  • Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa

    • Authors: Y Jo, L Jamieson, I Edoka, L Long, S Silal, JRC Pulliam, H Moultrie, …
    • Year: 2021
    • Citations: 57

  • Drinking and driving in Vietnam: public knowledge, attitudes, and practices

    • Authors: NT Tran, AM Bachani, VC Pham, JC Lunnen, Y Jo, J Passmore, …
    • Year: 2012
    • Citations: 49

  • Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York, and Texas

    • Authors: Y Jo, S Shrestha, I Gomes, S Marks, A Hill, G Asay, D Dowdy
    • Year: 2021
    • Citations: 37

  • Forecasting the value for money of mobile maternal health information messages on improving utilization of maternal and child health services in Gauteng, South Africa: cost …

    • Authors: A LeFevre, MA Cabrera-Escobar, D Mohan, J Eriksen, D Rogers, …
    • Year: 2018
    • Citations: 26

  • Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea

    • Authors: Y Jo, SB Kim, M Radnaabaatar, K Huh, JH Yoo, KR Peck, H Park, J Jung
    • Year: 2022
    • Citations: 23

  • Costs and cost-effectiveness analyses of mCARE strategies for promoting care seeking of maternal and newborn health services in rural Bangladesh

    • Authors: Y Jo, AE LeFevre, K Healy, N Singh, K Alland, S Mehra, H Ali, S Shaikh, …
    • Year: 2019
    • Citations: 23

Conclusion 🔖

Dr. Youngji Jo is a distinguished academic and researcher whose interdisciplinary expertise continues to shape the landscape of global public health. Her contributions to infectious disease modeling, health economics, and digital health interventions have significantly advanced our understanding of TB, HIV, and COVID-19. As she continues her research at UConn Health, her work remains at the forefront of data-driven solutions for global health challenges.